These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 9728332

  • 41. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
    Morrow G, Tanguay RM.
    Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
    [Abstract] [Full Text] [Related]

  • 42. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
    Wu G, Liu N, Rittelmeyer I, Sharma AD, Sgodda M, Zaehres H, Bleidissel M, Greber B, Gentile L, Han DW, Rudolph C, Steinemann D, Schambach A, Ott M, Schöler HR, Cantz T.
    PLoS Biol; 2011 Jul; 9(7):e1001099. PubMed ID: 21765802
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.
    Lock EA, Gaskin P, Ellis MK, McLean Provan W, Robinson M, Smith LL.
    Toxicology; 2000 Apr 03; 144(1-3):179-87. PubMed ID: 10781886
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice.
    van Ginkel WG, van Vliet D, van der Goot E, Faassen MHJR, Vogel A, Heiner-Fokkema MR, van der Zee EA, van Spronsen FJ.
    Nutrients; 2019 Oct 16; 11(10):. PubMed ID: 31623189
    [Abstract] [Full Text] [Related]

  • 56. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
    Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldámiz-Echevarría L, Spanish Working Group on Tyrosinemia type 1.
    Pediatr Int; 2011 Dec 16; 53(6):985-9. PubMed ID: 21752152
    [Abstract] [Full Text] [Related]

  • 57. Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells.
    Endo F, Sun MS.
    J Inherit Metab Dis; 2002 May 16; 25(3):227-34. PubMed ID: 12137232
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct 10; 58(1505):e132. PubMed ID: 27701365
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.